| Style | Citing Format |
|---|---|
| MLA | Firoozabadi M, Nooralishahi B, Rezaeitazangi F. "Analgesia and Silymarin: What Are the Opportunities and Challenges?." Molecular Pain, vol. 21, no. , 2025, pp. -. |
| APA | Firoozabadi M, Nooralishahi B, Rezaeitazangi F (2025). Analgesia and Silymarin: What Are the Opportunities and Challenges?. Molecular Pain, 21(), -. |
| Chicago | Firoozabadi M, Nooralishahi B, Rezaeitazangi F. "Analgesia and Silymarin: What Are the Opportunities and Challenges?." Molecular Pain 21, no. (2025): -. |
| Harvard | Firoozabadi M, Nooralishahi B, Rezaeitazangi F (2025) 'Analgesia and Silymarin: What Are the Opportunities and Challenges?', Molecular Pain, 21(), pp. -. |
| Vancouver | Firoozabadi M, Nooralishahi B, Rezaeitazangi F. Analgesia and Silymarin: What Are the Opportunities and Challenges?. Molecular Pain. 2025;21():-. |
| BibTex | @article{ author = {Firoozabadi M and Nooralishahi B and Rezaeitazangi F}, title = {Analgesia and Silymarin: What Are the Opportunities and Challenges?}, journal = {Molecular Pain}, volume = {21}, number = {}, pages = {-}, year = {2025} } |
| RIS | TY - JOUR AU - Firoozabadi M AU - Nooralishahi B AU - Rezaeitazangi F TI - Analgesia and Silymarin: What Are the Opportunities and Challenges? JO - Molecular Pain VL - 21 IS - SP - EP - PY - 2025 ER - |